BidaskClub upgraded shares of Corium International (NASDAQ:CORI) from a strong sell rating to a sell rating in a research note published on Wednesday morning.
Several other equities research analysts also recently issued reports on CORI. Zacks Investment Research upgraded shares of Corium International from a hold rating to a buy rating and set a $13.00 price objective for the company in a research report on Thursday, March 22nd. Cantor Fitzgerald restated a buy rating and set a $14.00 price objective on shares of Corium International in a research report on Tuesday, March 27th. ValuEngine upgraded shares of Corium International from a hold rating to a buy rating in a research report on Monday, April 2nd. Finally, HC Wainwright set a $14.00 target price on shares of Corium International and gave the stock a buy rating in a report on Tuesday, May 15th. Two research analysts have rated the stock with a sell rating and six have issued a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $13.00.
Shares of CORI stock opened at $9.12 on Wednesday. The company has a debt-to-equity ratio of 1.89, a current ratio of 8.11 and a quick ratio of 7.95. The company has a market cap of $322.92 million, a price-to-earnings ratio of -5.56 and a beta of 1.54. Corium International has a 12-month low of $6.95 and a 12-month high of $13.93.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC increased its holdings in shares of Corium International by 14.0% during the fourth quarter. Renaissance Technologies LLC now owns 96,900 shares of the biopharmaceutical company’s stock worth $931,000 after purchasing an additional 11,900 shares during the period. Geode Capital Management LLC increased its holdings in shares of Corium International by 6.0% during the fourth quarter. Geode Capital Management LLC now owns 223,536 shares of the biopharmaceutical company’s stock worth $2,147,000 after purchasing an additional 12,745 shares during the period. MetLife Investment Advisors LLC bought a new position in shares of Corium International during the fourth quarter worth approximately $123,000. DekaBank Deutsche Girozentrale bought a new position in Corium International in the first quarter valued at approximately $167,000. Finally, Schwab Charles Investment Management Inc. increased its stake in Corium International by 47.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock valued at $476,000 after acquiring an additional 15,909 shares during the last quarter. 95.07% of the stock is currently owned by institutional investors.
About Corium International
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.